Phase IIIGLP-1
Compound 61412
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061412
Risk Class
MODERATE
Last Audit
Jan 27, 2108
Research Abstract
GLP-1 candidate engineered for endocrine support initiatives with automated dossier coverage.
Compound 61412 is a glp-1 asset inside glp-1 innovation track initiatives, optimized for endocrine support and performance longevity.
The dossier currently sits in phase iii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061412 with updates logged 2108-01-27.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Endocrine supportPerformance longevity
Nomenclature
CX-61412GLP-1 Program 61412
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061412
- [2] Operations Pulse • GLP-1 innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61412